Subdividing patients from the TCGA AML dataset (TCGA-LAML) according to their clinical risk classification, we found that patients with a favorable risk (n = 32) had significantly higher MLKL expression compared to patients in the intermediate (n = 103) or poor (n = 36) risk (Fig. 1C). This evidence concerns the gene MLKL and acute myeloid leukemia.